Pfizer Pakistan, a prominent international pharmaceutical corporation, has divested its entire operations to Lucky Group, exiting the Pakistani market.
Pfizer’s exit underscores a trend in the pharmaceutical sector, where major international firms have been withdrawing from the local market.
The acquisition by Lucky Group, a prominent conglomerate with varied business interests in Pakistan, signifies a strategic expansion into the pharmaceutical sector, underscoring the growing prominence of local enterprises in this field. The transition reflects the dynamic shifts within the local market landscape and highlights the resilience and ascending trajectory of the Pakistani pharmaceutical industry.
Over the past twenty years, the pharmaceutical sector in Pakistan has seen a notable shift, with local companies expanding their domestic market presence and enhancing their drug manufacturing and innovation capabilities. The exit of Pfizer and similar moves by other international firms have opened opportunities for local players to consolidate their positions and capture a larger share of the market.
The next strategic focus for the Pakistani pharmaceutical industry appears to be the development of export markets. With a solid foundation at home, local companies are poised to venture into international markets, leveraging their enhanced manufacturing capabilities and competitive pricing to establish a global footprint.
The progression towards international market penetration is anticipated to bring about a new era of growth and opportunities for the industry, positioning Pakistan as a significant player in the global pharmaceutical landscape.
